Nosocomial Influenza Surveillance 2018 - 2022 (NOSOGRIPPE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03413228|
Recruitment Status : Not yet recruiting
First Posted : January 29, 2018
Last Update Posted : January 30, 2018
Hospital-acquired influenza is associated with significant morbidity and mortality in hospitalized patients notably elderly patients. Furthermore, it is also associated with a large economic impact for the hospitals.
The transmission of influenza has been mostly reported in pediatric and long-stay units. The chains of transmission of influenza in acute-stay units have to be describe in order to prevent and control potential outbreaks. Furthermore, to know clinical symptoms seems to be important in order to identify potential sources of virus as soon as possible and to set up appropriate hygiene prevention measures. Moreover, the definition of the hospital-acquired influenza has to be harmonized for all over the studies, especially concerning the delay between the admission in the hospital and the symptoms onset.
The aim of this study is to describe the hospital-acquired influenza in a french university hospital of around 800 beds
|Condition or disease||Intervention/treatment|
|Hospital-Acquired Infection Influenza||Other: Questionnaire|
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Surveillance of Nosocomial Influenza at Edouard Herriot University Hospital, Lyon, France.|
|Anticipated Study Start Date :||February 2018|
|Estimated Primary Completion Date :||June 2018|
|Estimated Study Completion Date :||June 2022|
|Influenza-like illness group||
An interview to collect some informations will be done: demographic informations, medical history, vaccination against influenza status, symptoms and virological informations. Then, a nasal swab was performed in order to identified the influenza virus.
- Proportion of patients and health-care workers who present an influenza illness. [ Time Frame: 5 days maximum ]
An interview to collect some informations will be done to evaluate if participants present symptoms of an inflenza illness (fever > 37,8°C or/and cough or sore throat).
Then, a nasal swab will be performed in order to identified the influenza virus.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03413228
|Contact: Philippe VANHEMS, MD PhD||0472110719 ext +firstname.lastname@example.org|
|Infection Control unit. Edouard Herriot hospital Lyon - France||Not yet recruiting|
|Lyon, France, 69003|
|Contact: Philippe VANHEMS, MD PhD 0472110719 ext +33 email@example.com|